Creative Biolabs is a professional manufacturer of Antibody-cytokine Fusion Proteins (ACFPs). According to the extensive experience and achievements in genetic engineering and biotechnology field, Creative Biolabs has developed a series of functional cytokine fusion antibodies, simultaneously, a growing number of new antibody-cytokine fusion proteins are under development as well. These immunocytokine molecules were shown to have striking anti-tumor activity and may provide a useful approach to the treatment of cancer.
Antibody-cytokine fusion proteins, which consist of cytokines fused to an antibody, have the properties of all components and acquire advantages compared to proteins alone. Structurally, there are two main types of ACFPs which cytokines can be alternatively fused to either whole immunoglobulin (Ig fusion) or antigen-binding fragments such as Fabs, single-chain variable fragments (scFvs) or divalent derivatives thereof, e.g. diabodies. Moreover, differences in the composition of the fusion proteins are also due to the cytokine itself. Many cytokines are composed of a single monomeric protein domain (e.g. IL-2 and IFN-a), while others are homodimeric (e.g. IL-10 and IFN-γ), homotrimeric molecules (e.g. TNF and TRAIL) or heterodimeric (e.g. IL-12 and IL-27). Each cytokine can be fused at the amino- or carboxy-terminus of the antibody, which depends on the structure of the cytokine and antibody, and in order to conserve the biological activity of both components. Further improvements also include the fusion of different cytokines to an antibody.
Advantages of Antibody-cytokine Fusion Proteins:
• Good biological activity of both components
• Low or non immunogenic
• Endotoxin free
• Subnanomolar high affinity
• High production yield
• Great stability
• Outstanding solubility in aqueous solutions
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.